We have shown that survivin is frequently transcribed and translated in adult B-ALL, but not healthy donor samples, suggesting this may be a promising target patient group for survivin-mediated immunotherapy. The gene discussed is BIRC5; the disease is precursor B-cell acute lymphoblastic leukemia.